Literature DB >> 524296

The evolution of teratological testing.

J G Wilson.   

Abstract

The beginnings of mammalian experimental teratology in this century are briefly reviewed and it is noted that prior to 1960 a degree of sophistication in concept and technology had already been achieved. Thus, contrary to claims that teratology had its beginning with the thalidomide catastrophe, a modest but expanding activity and body of knowledge already existed before this unfortunate event. This activity and this knowledge, however, were largely confined to academic and research institute laboratories and made little impact on the agencies in medicine, government and industry which oversaw public health and safety and set policies intended to preserve them. No individual, group, or agency can rightly be blamed for not having sooner brought together the concepts and methodology needed for meaningful animal testing and the regulatory insignt and experience needed intelligently to apply test data to human safety evaluation and experience needed intelligently to apply test data to human safety evaluation. To accomplish this liaison seems to have required the largest toxicological catastrophe yet recorded in human history. The major events leading to formulation of the first standardized guidelines are reviewed, but it is emphasized that even today the best animal testing can only provide a limited statement of probability regarding human risk vis-à-vis safety.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 524296     DOI: 10.1002/tera.1420200205

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  2 in total

Review 1.  Biomarkers in paediatric research and practice.

Authors:  B P Lanphear; C F Bearer
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

2.  Identifying signals of potentially harmful medications in pregnancy: use of the double false discovery rate method to adjust for multiple testing.

Authors:  Alana Cavadino; David Prieto-Merino; Joan K Morris
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.